本帖最后由 老马 于 2012-1-13 21:20 编辑
9 G+ e1 L! z, T( B
- Z0 X5 }: V5 O" j! ~2 v$ j' {3 C. W爱必妥和阿瓦斯丁的比较2 ?4 C% I1 a( l1 N
1 J+ v( x) t5 a1 X% t7 e) y
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" c8 i$ f8 u7 t, M2 {1 w) Y
7 {+ [- P1 z* M, b* k! g' v
% ]8 _' r O& G8 |9 S
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/: d0 ~# P9 p/ u# l3 B8 L; ]& c5 c9 Z
==================================================$ p- B; ^# k" X O
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
1 Y2 i0 B5 E- F- t6 ^Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* @3 C8 N1 K; L: JResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* `" R* ] I" P" A {$ y0 Z
|
显身卡
\& d3 N. R+ A2 D6 s1 f |
